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A B S T R A C T   
Colistin is drug of choice for treatment of carbapenem-resistant Acinetobacter baumannii infections. Unfortu-
nately, global increase in clinical outbreaks of colistin and carbapenem resistant A. baumannii infections is on the 
rise and cause public health concern. In the present study, a total of 187 A. baumannii recovered from specimens 
of 240 patients admitted to intensive care units (ICUs) of two hospitals in Kerman, Iran during 2017–2018. 
Among the isolates, we found four extensive drug-resistant (XDR) with Minimum Inhibitory Concentration (MIC) 
≥4 μg/mL against colistin. The colistin-resistant (Col-R) isolates harbored blaOXA–51 and blaOXA-23 carba-
penemase genes, exhibited resistance to all antibiotic classes except tigecycline and ampicillin-sulbactam. They 
belonged to clonal complex 2, a new MLST type 1752 and displayed identical RAPD-PCR fingerprints. Phylo-
genetic tree analysis suggested that, the Col-R A. baumannii emerged by endogenous mutations rather than 
acquisition of preexisting clones. Expressions of pmrCAB by quantitative real-time PCR (qRT-PCR) revealed 8 and 
7 folds increased in the transcription levels of pmrB/C genes in strain 1 grown in presence of 16 μg/mL colistin (p 
≤ 0.01). However, no change in the expression of the pmrA was observed. Furthermore, DNA sequencing of Col-R 
genes illustrated three nonsynonymous substitutions in the LpxA (N136 → K), LpxC (P293 → Q), and PmrB (V21 
→ F, S28 → R, I149 → F) in the strains 1 and 3, respectively showing MIC 32 μg/mL against colistin. Multiple 
amino acids alignments demonstrated several substitutions in N-terminal region of PmrB. In conclusion, the 
above results provide valuable insights into the mechanism of Col-R in A. baumannii and the expressions of 
relative genes.   
1. Introduction 
Acinetobacter baumannii has been an important nosocomial pathogen 
being frequently implicated in ventilator-associated pneumonia, blood 
stream, urinary tract, and soft tissue infections (Alsan and Klompas, 
2010). Carbapenem antibiotics such as imipenem or meropenem are 
widely used for the treatment of Acinetobacter infections in Middle East, 
Southeast Asia. Nevertheless, the rapid emergence of A. baumannii 
strains resistant to all β-lactams including carbapenem, illustrates the 
potential of this organism to respond swiftly to changes in selective 
environmental pressure (Azizi et al., 2016a, 2016b; Gordon and Ware-
ham, 2010; Manchanda et al., 2010; Perez et al., 2007; Yun et al., 2012). 
Therefore, colistin is last line therapeutic for carbapenemase producing 
multidrug-resistance (MDR) A. baumannii isolates. However, global in-
crease in the clinical outbreaks of colistin and carbapenem resistant 
A. baumannii infections is on the rise and cause public health concern 
(Qureshi et al., 2015). Since, first case of Col-R Acinetobacter spp., in the 
Czech Republic in 1999, the incidence of Col-R is progressively 
increasing in past decade (Hejnar et al., 1999). Epidemiological data 
indicate that, the number of Col-R A. baumannii hospital isolates has 
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been increased from 0.9% in 1999 to 7% in 2012 (Cai et al., 2012). The 
highest resistance rate reported from India (53%), followed by Iran 
(48%), Spain (40.7%), and South Korea (30%) (Asif et al., 2018). Recent 
study indicated a clonal expansion of Col-R A. baumannii in South Af-
rican hospitals (Snyman et al., 2020). Nevertheless, the prevalence of 
Col-R A. baumannii hospital isolates in South-East Asia and Eastern 
Mediterranean were higher than other regions of the world during 
2000–2017 (Pormohammad et al., 2020). 
Three mechanisms of colistin-resistance have been reported in 
A. baumannii so far. First, soaring-level of colistin resistance (MIC >32 
μg/mL) can result from a complete loss of lipid A, create a lipopoly-
saccharide (LPS/LOS) deficient outer membrane. This mechanism of 
Col-R results from spontaneous point mutations within one of the lipid A 
biosynthesis lpxA, lpxC, or lpxD genes (Moffatt et al., 2010). A tran-
scriptomic study comparing gene expression between LPS-deficient and 
wild type strains demonstrated increased expression of genes involved in 
the synthesis and transport of lipoproteins, phospholipids, and poly- 
β-1,6-N-acetylglucosamine suggesting a compensatory response to the 
loss of LOS in the bacterial outer membrane (Henry et al., 2012). The 
second Col-R mechanism in A. baumannii involves modification of the 
lipid A component in LPS, which is mediated by the pmrCAB operon. The 
two-component PmrA/B regulates the expression of PmrC, which facil-
itates phosphoethanolamine (pEtN) addition to lipid A. This phenome-
non reduces the net negative charge of the outer layer, thereby affecting 
the binding of colistin to the cell membrane (Nhu et al., 2016; Raetz 
et al., 2007; Trimble et al., 2016). It has been reported that, clinical 
isolates of A. baumannii developed Col-R during failed treatment have 
mutations in pmrA/B genes (Olaitan et al., 2014; Park et al., 2011). In 
A. baumannii, the coding region of pmrB gene seems more prone to 
mutations as compared to the pmrA (Adams et al., 2009; Delgado et al., 
2006; Lee et al., 2004; Yoon et al., 2013). Similarly, the work of Zhang 
et al. (2017) showed that, although expressions of the pmrA/B might be 
necessary for colistin resistance but amino acid alterations might not be 
essential. Furthermore, resistance due to lipid A modifications by a 
mutation in PmrAB two-component regulatory system has a relatively 
low biologic cost, especially concerning A. baumannii virulence (Wand 
et al., 2015). Third mechanism of Col-R involve, activation of a broad- 
spectrum efflux pump by mutation in the ΔemrB gene family or 
changes in membrane permeability through reduction in the number of 
entry channels, like ompA porin (Uppalapati et al., 2020; Lin et al., 
2017). Recent research on mechanism of Col-R in A. baumannii suggest 
that, the disruption of the global regulator H-NS by insertion sequence 
ISAba125 into lpxA, lpxC and lpxD is playing an important role in the 
Col-R A. baumannii. H-NS also negatively regulated the expression of the 
pmrC homologous eptA, which in turn changes lipid A by pEtN addition 
(Deveson et al., 2018; Moffatt et al., 2011). In addition, a novel plasmid 
(pAb-mcr-4.3) harbouring mcr-4.3 gene with a Tn3-like transposon has 
been found in the A. baumannii. The E. coli BL21 transformed with pET- 
26b-mcr-4.3 plasmid gained colistin resistance with MIC of 8μg/mL 
(Sorenson et al., 2020). 
Despite several investigations on the prevalence of Col-R 
A. baumannii worldwide, few studies focused on the molecular mecha-
nism and expression of colistin resistant associated genes in the presence 
and absence sub-MIC of colistin. 
The objectives of this study were to evaluate the prevalence, type and 
position of mutations in lipid A biosynthesis lpxA, lpxC, lpxD genes and 
pmrAB two-component regulatory system, to assess the molecular typing 
and expressions of the pmrCAB genes in presence and absence of colistin 
sub-MICs, and finally to elucidate the phylogenetic tree and multiple 
sequence alignment of PmrA/B protein. 
2. Materials and methods 
2.1. Samples and bacterial identification 
In a retrospective study from July 2017 to May 2018, a total of 187 
nonduplicate A. baumannii isolates were collected from bronchoalveolar 
lavage (BAL), blood, urine, wound, and cerebrospinal fluid (CSF) of 240 
patients admitted in ICUs of two university affiliated hospitals (A and B) 
in Kerman, Iran. The specimens were inoculated in to 5 mL sterile Stuart 
transport broth (Merck, Germany) and transferred within 24 h to 
Department of Microbiology laboratory for further study. Bacterial 
identification of Acinetobacter spp. was initially performed by conven-
tional diagnostic tests including Gram-staining and biochemical tests 
such as catalase, citrate utilization, oxidase, OF and indole tests as 
described previously (Kulkarni et al., 2017; Shakibaie et al., 2012). They 
were confirmed genetically to species level by multiplex-PCR using 
primers (Supplementary 1A) specifically amplifying an internal 208 bp 
internal fragment of the 16S–23S rRNA intergenic spacer (ITS) region 
and highly conserved 425 bp region of the recA gene of A. baumannii 
(Chen et al., 2007). The PCR products were then sequenced by ABI Prism 
373 DNA Sequencer (Applied Biosystems 373/3730XL, Bioneer, Korea). 
The obtained sequences were compared against known sequences in the 
National Centre for Biotechnology Information (NCBI) database using 
Blast comparison algorithm with default settings. Simultaneously, we 
used standard culture of A. baumannii ATCC 19606 as positive control. 
2.2. Ethics approval 
This study reviewed and approved by the Research Ethics Committee 
of Faculty of Medicine – Kerman University of Medical Sciences Kerman, 
Iran according to reference number IR.KMU.REC.1397.034. 
2.3. Determination of antimicrobial susceptibility 
The antimicrobial susceptibility test of Col-R A. baumannii isolates 
against 13 antibiotics was carried out using Kirby-Bauer disk diffusion 
method and the results was interpreted according to the European 
Committee on Antimicrobial Susceptibility Testing protocol (EUCAST; 
www.eucast.org/clinical_breakpoints/). The antibiotic disks used in this 
study were as follow; ceftazidime (30 μg), ciprofloxacin (5 μg), levo-
floxacin (5 μg), tobramycin (10 μg), ceftriaxone (30 μg), imipenem (10 
μg), meropenem (10 μg), gentamicin (10 μg), piperacillin-tazobactam 
(100/10 μg), amikacin (10 μg), tigecycline (15 μg) and ampicillin- 
sulbactam (10/10 μg). Besides, we performed Minimum Inhibitory 
Concentrations (MICs) of imipenem and colistin by broth microdilution 
method as described by Clinical and Laboratory Standard guidelines 
(CLSI, 2019). The isolates with colistin MIC ≥4 μg/mL were considered 
resistant. A. baumannii ATCC 19606 and Escherichia coli ATCC 25922 
were used for quality control. All antibiotic was purchased from Mast 
Group Ltd., Manchester, UK. The A. baumannii phenotypes were defined 
as MDR, XDR and pan-drug resistance (PDR) according to the interna-
tional expert proposal for interim standards guidelines (Magiorakos 
et al., 2012). 
2.4. Detection of ESBL, carbapenemase and class 1 integrons 
All Col-R isolates were first screened phenotypically for presence of 
extended spectrum β-lactamase (ESBL), by double disk synergy test 
using cefpodoxime and cefpodoxime + clavulanic acid, cefotaxime +
cefotaxime clavulanic acid, carbapenemase enzymes by modified Hodge 
test, and metallo-β-lactamase by imipenem + EDTA strip test, respec-
tively (Safari et al., 2015). They further screened for presence of 
following genes; blaCTXM, blaPER, blaSHV, blaVEB, blaGES, blaTEM, 
blaOX-A23, blaOXA-51 blaOXA-24, blaOXA-58, blaVIM, blaIMP and 
blaNDM genes by multiplex-PCR technique (Peymani et al., 2017; Safari 
et al., 2015). Furthermore, PCR assay was performed to amplify inte-
grase region (intI1) of class 1 integrons as described previously (Azizi 
et al., 2016a, 2016b). The primers and respective sequences are shown 
in Supplementary 1A. 
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2.5. Clonal relatedness and multilocus sequence typing 
Furthermore, the clonal relationship similarities of the Col-R isolates 
were carried out by random amplified polymorphic DNA (RAPD)-PCR 
method using following sequences 5′- ACGGCCGACC-3′ and 5′- 
AGCGGGCCAA-3′ (Azizi et al., 2016a, 2016b). The isolates were ana-
lysed on the basis of a unique DNA fingerprint pattern using Gel 
Compare II software version 5.0 (Applied Maths, Sint-Matens-latem, 
Belgium). Dice comparison and clustering correlation coefficient 
calculated by UPGMA to find degree of homology. Similarity coefficient 
90% considered as cut-off value. 
Furthermore, to find out sequence type of Col-R A. baumannii iso-
lates, we performed MLST typing according to Oxford’s scheme (Sny-
man et al., 2020). Here, we amplified seven housekeeping genes gltA, 
gyrB, gdhB, recA, cpn60, gpi, rpoD under the following conditions; 30 
cycles (denaturation at 94 ◦C for 1 min, annealing at 55 ◦C for 1 min, and 
extension at 72 ◦C for 2 min) preceded by a 2 min denaturation at 94 ◦C 
and followed by a 2 min extension at 72 ◦C. The primers for MLST are 
presented in Supplementary 1A. PCR products were directly purified 
from the reaction mixture with the QIAquick PCR purification kit 
(QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s 
recommendations. Sequencing of internal conserved fragments of about 
450 bp of the selected housekeeping genes was performed by ABI Prism 
373 DNA Sequencer (Applied Biosystems 373/3730XL, Bioneer, Korea). 
The obtained sequences were analysed using the VectorNTI Software 
package Version 11.5.1 and were compared with the A. baumannii 
database at MLST website (http://pubmlst.org/abaumannii/). The 
eBURST algorithm program version 3 (http://eburst.mlst.net) was used 
to group the isolates into clonal complexes (CCs). The similarities among 
the allelic profiles were compared by unweighted pair-group method 
with arithmetic averages (UPGMA), available in MEGA suite program 
version 2.1 (http://www.megasoftware.net). 
2.6. PCR-sequencing, gene annotation and phylogenetic tree construction 
The pmrA, pmrB, lpxA, lpxC, and lpxD genes were amplified and 
sequenced in both strands’ directions by ABI 373 Prism DNA sequencer 
(Applied Biosystems 373/3730XL model, Bioneer, Korea). The nucleo-
tides and deduced proteins sequences were then blasted to known nu-
cleotides and protein sequences in National Center for Biotechnology 
Information (NCBI) database by using Basic Local Alignment Search 
Tool (BLAST) program (http://www.ncbi.nlm.nih.gov/BLAST/). Genes 
annotated by the Microbial Genome Annotation Pipeline (MiGAP2) 
program. Nevertheless, the multiple sequence alignments between the 
putative amino acid sequences of PmrA/B and closely related sequences 
were determined using UniProtKB database (www.uniprot.org/). To 
find the percent of identity between PmrA/B in this study with other 
related sequences, the phylogenetic trees were constructed by neighbor 
joining method (https://www.ncbi.nlm.nih.gov/genbank/blast) using 
PHYLIP package software (version 3.695). Bootstrapping was performed 
(1000 replicates) to assess the confidence values of the cluster formed 
with the distance matrix 90% similarity cut-off. 
2.7. Nucleotide sequence accession numbers 
The sequences were deposited in GenBank database under accession 
numbers MN787069.1 (lpxA), MN787070.1 (lpxC), MN787071.1 
(lpxD), MN787072.1 (pmrA), MN787073.1 (pmrB) as shown in Sup-
plement 2. 
2.8. Detection of mcr-1 and mcr-2 plasmid related genes 
The presence of mcr-1 and mcr-2 plasmid relate genes in Col-R 
A. baumannii isolates were determined using specific primers as shown 
in Supplementary 1A. DNA extraction was done by boiling method and 
10 μL of the supernatant was used for PCR assays as described previously 
(Rebelo et al., 2018). 
2.9. Expression of pmrCAB by qRT-PCR 
The relative quantitative real-time PCR (qRT-PCR) of Col-R 
A. baumannii was performed to assess the expression of pmrA, pmrB 
and pmrC genes in presence and absence of sub-MIC concentrations of 
colistin. Briefly, 16 h grown culture of Col-R A. baumannii were in-
oculates in two sets of 5 mL sterile Tryptic Soy broth (BioMérieux, 
Marcy-I’Etoile, France), one containing colistin concentrations ranging 
from 2 to 16 μg/mL. Total RNA was extracted by RNA extraction kit 
(BIOFACT, Seoul, Korea) as described by the manufacturer. The samples 
normalized by cell density prior to RNA extraction according to protocol 
described previously (Livak and Schmittgen, 2001). Harvested RNA 
samples were quantified by 260/280 and 260/230 nm absorbance ratio 
using the Nano Drop spectrophotometer (Thermo Fisher Scientific, MA, 
USA). The list of primers and their sequences used for qRT-PCR exper-
iments are shown in Supplementary 1B. The extracted RNA was sub-
jected to reverse transcription using the BIOFACT Korea reverse 
transcription kit. Amplification was carried out by StepOne™ Software 
v2.3e (Applied Biosystems, Foster City, CA, USA) using Quantifast® 
SYBR®Green qRT-PCR. For amplification purpose, 25 μL of BIOFACT™ 
2× Real-Time PCR master mix solution (BIOFACT, Korea), 10 μL of each 
primer, 2× Taq PCR Pre-Mix, 5 μL of 20 ng cDNA template, 50 μL 
Table 1 
Demographic conditions and antimicrobial susceptibility of four colistin-resistant and seven-selected colistin-sensitive A. baumannii isolates investigated in this study.  
Isolate 
number 
Sex Age Unit Hospital Sample 
site 
Treatment* CP CR AK CZ TN TN TG LEV MEM SAM PR CLS 
MIC* 
IMP 
MIC 
Colistin resistant isolates 
1 F  61 ICU A CSF Monotherapy R R R R R S S R R S R  32  125 
2 F  44 ICU A BAL Monotherapy R R R R R R S R R S R  8  125 
3 M  42 ICU A BAL Monotherapy R R R R R R S R R S R  32  125 
4 M  39 ICU A BAL Monotherapy R R R R R R S R R I R  4  125  
Colistin sensitive isolates 
1 F  90 ICU A BAL Monotherapy R R R R R R S R R S S  0.5  64 
2 M  41 ICU B W/C Monotherapy R R S R S R S R S S S  1  2 
3 M  20 ICU B BAL Monotherapy S R R R R S S R S S R  0.5  0.5 
4 F  21 ICU A B/C Monotherapy S R R R S R S S S S S  0.5  1 
5 M  12 ICU A Urine Monotherapy R R R R I R S R R S S  0.5  16 
6 M  84 ICU A BAL Monotherapy R R R R R R S R S S R  1  4 
7 F  77 ICU A BAL Monotherapy R R R R R R S R R S R  2  64 
Abbreviations: M = Male, F = Female, ICU = intensive care unit, A = Afzalipour hospital, B = Bahonar hospital, CSF = cerebrospinal fluid, BAL = Broncho alveolar 
lavage, BC = blood culture, ORT = orthopedic, WC = wound culture, R = resistance, I = intermediate, S = sensitive, MEM = meropenem, AK = amikacin, CZ =
ceftazidime, CLS = colistin, CR = ceftriaxone, CP = ciprofloxacin, IMP = Imipenem, LEV = levofloxacin, PR = Piperacillin, SAM = Ampicillin-sulbactam, TN =
tobramycin, TG = tigecycline. *MIC = minimum inhibitory concentration (μg/mL). MICs repeated twice and same observation was obtained. 
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Random Hexamer (1×) and 1.0 μL RNase free water were added. The 
qRT-PCR was carried out with the following profile: 1 cycle at 95 ◦C for 
30 s, followed by 40 cycles at 95 ◦C for 5 s, 60 ◦C for 10 s, and 72 ◦C for 
20 s. Data were compared with the housekeeping gene 16S rRNA using 
the threshold cycle (ΔΔCT) method (relative), and the obtained values 
were then normalized against the values for the susceptible A. baumannii 
ATCC 19606 strain. Standard melting curves with known molarity used 
to estimate copy number of mRNAs per cell. A negative control without 
reverse transcriptase was included to detect DNA contamination and 
A. baumannii ATCC 19606 used as positive control. The levels of ex-
pressions were measured using 2− ΔΔCt Pfaffl method as fold change ratio 
between target genes in triplicate and the 16S-rRNA reference gene 
(Pfaffl, 2001). Differences were assessed by Student’s t-test for consid-
eration as statistically significant. 
Fig. 1. A) PCR gel electrophoresis of blaOXA-51 and blaOXA-23 carbapenemase genes in four colistin resistant A. baumannii hospital isolates. B) Schematic represen-
tation of RAPD-PCR fingerprints Col-R A. baumannii investigated in present study. In case of RAPD-PCR, DNA banding patterns were analysed by using Gel Compare II 
software version 5.0. Degrees of homology were determined by Dice coefficient and clustering was calculated by the UPGMA with 90% similarity cut-off. 
Fig. 2. Expressional analyses of two-component regulatory systems pmrCAB. The level of transcripts without colistin was compared to that of isolates with sub-MIC 
concentrations of colistin ranging from 2 to16 μg/mL after being normalized with the reference gene 16S-rRNA and the susceptible isolate A. baumannii ATCC 19606. 
The standard curve with a known molarity has been calculated to estimate the copy numbers of mRNAs per cell. * P < 0.01was considered as significant. 
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2.10. Statistical analyses 
All analysis was performed using IBM SPSS version 22. P-values 
≤0.01 was considered statistically significant. 
3. Results 
3.1. Bacterial isolates and patient’s demographic condition 
We recovered a total of 187 nonduplicate clinically relevant isolates 
of A. baumannii from specimens of patients admitted in different ICUs of 
two hospitals in Kerman, Southeast of Iran. The most positive specimens 
were obtained from BAL 71.6% (n = 127), followed by wound 9.1% (n 
= 17), CSF 9.1% (n = 17), blood 4.3% (n = 8), and the remaining 8.66% 
(n = 18) were collected from urine samples. All the colistin-resistant 
isolates were from hospital A. The patients were hospitalized for 15 to 
20 days in the ICUs of hospital A and B (Table 1). Thirty-two percent (n 
= 40) of the patients were female whereas, 67% (n = 60) were male with 
the mean age of patients was ±52.2 years old. They were under anti-
biotic therapy with the third generation of cephalosporins for 4 days 
(Table 1). None of them were treated with colistin previously as an 
antimicrobial drug and ever traveled abroad. 
3.2. Antimicrobial susceptibility testing 
The results of antimicrobial susceptibility tests including broth 
microdilution MIC for colistin and imipenem are shown in Table 1. MDR 
isolates were the most predominant constituted 66.8% total isolates, 
XDR phenotype consisted of 5.1% A. baumannii isolates, however, no 
pandrug-resistant (PDR) phenotype was found in this study. Four XDR 
isolates with MICs ranges from 4 to 32 μg/mL against colistin and 125 
μg/mL against imipenem were selected for further study (Table 1). Col-R 
isolates were also resistant to ceftazidime, ciprofloxacin, levofloxacin, 
tobramycin, ceftriaxone, imipenem, meropenem, gentamicin, 
piperacillin-tazobactam, and amikacin, but they were sensitive to tige-
cycline and ampicillin-sulbactam, respectively. 
3.3. ESBL, carbapenemase and mcr-1, mcr- 2 genes 
Colistin-resistant A. baumannii isolates were subjected to PCR 
screening for the presence of ESBL, MBL, carbapenemase, and mcr-1, 
mcr- 2 plasmid mediated genes. All the isolates harbored blaOXA-51 and 
blaOXA-23 genes as shown in Fig. 1A, while no other carbapenemase, 
MBL, ESBLs, mcr- 1 or mcr- 2 genes and class 1 integrons were detected 
in this study. 
Fig. 3. A) Phylogenetic evaluation of PmrA protein; B) Phylogenetic distance analysis of PmrB protein. For phylogenetic tree, the evolutionary history was inferred 
automatically by the Neighbor-Joining (NJ) algorithm that uses a matrix of pairwise distances estimated under the Jones–Thornton–Taylor (JTT) model for amino 
acid sequences. The bootstrap derived from 1000 replicates. 
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3.4. Molecular typing 
Molecular epidemiology typing by RAPD-PCR technique showed an 
identical banding pattern of four Col-R isolates A. baumannii in agarose 
gel. This was supported by the construction of a dendrogram and anal-
ysis of the percent identity using Gel compare software. The results 
revealed more than 90% similarity in fingerprints (Fig. 1B). Therefore, 
we suggest the Col-R isolates emerged from a single clonal lineage 
(singleton). The RAPD-PCR results were further confirmed by MLST 
typing. The data indicated that all Col-R isolates belonged to a novel 
MLST type assigned as ST-1752. Comparing to other STs, we found that, 
this allele was domestic and has not been reported elsewhere. Further, 
analysis of the MLST sequences by eBURST revealed that the strains 
belonged to clonal complex 2 (CC2) which has previously been 
associated with divergent blaOXA-23 producing strains in several 
countries worldwide. 
3.5. Expressions of pmrCAB genes in presence and absence of colistin 
To evaluate the association between colistin resistance and upregu-
lation of pmrCAB operon in Col-R A. baumannii, the transcriptional level 
of these genes was quantified in the presence and absence of sub-MIC 
concentrations of the colistin. Here, we performed total RNA extrac-
tion from harvested cells grown in presence and absence of colistin, 
reverse transcribed into the first strand of cDNA followed by qRT-PCR 
estimation. The results indicated that the expression of pmrB in Col-R 
strain 1 was increased 8-fold in the presence of 16 μg/mL colistin 
(Fig. 2). This was associated with 7-fold increase in pmrC transcriptional 
Fig. 3. (continued). 
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activity. In contrast, the Col-R strains 2, 3, and 4 did not show significant 
fold change increase in the expression of pmrB in presence of colistin, 
respectively (Fig. 2). Furthermore, no significant changes in the mRNA 
level of pmrA were observed. Therefore, the results evidenced a strain- 
dependent response to the colistin resistance onset highly variable 
among the Col-R strains. 
3.6. Sequencing, mutational analysis and phylogenetic tree assessment 
To find out the type and position of mutations in lpx and pmrA/B 
genes which are known as hotspots for elevated MICs against colistin, we 
performed DNA sequencing as shown in Table 2 and Supplement 2. 
Three different non-synonymous substitutions in lpx genes (a single 
transversion mutation in lpxA [N → K] at position 136 in the strain 1, 
two substitutions in the lpxC at positions 227 [P → Q] and 293 [G → R] 
in strains 3, 4, and three-point mutations in the lpxD at positions 318 [(K 
→ T], 320 [I → E], 322 [R → V] in strain 2) were detected in this study. 
Furthermore, a single point mutation in pmrA at position 218 (Q → K) 
was observed in the strains 1, 2, and 3 (Table 2). Interestingly, strains 2, 
3, and 4 showed the same amino acid substitutions in lpxD at position 
318 [(K → T]. We found; all clinical Col-R isolates harbored at least one- 
point mutation in the pmrB gene including a L → F substitutions at 
Fig. 4. Amino acids alignments and the schematic representation of position of mutations in PmrB protein of colistin-resistant A. baumannii strain 1. The PmrB 
sequence was aligned with closely related sequence in the UniProtKB database. The point mutations are showed with arrow and domains with different color box. 
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position 5. The highest number of mutations was observed in the pmrB of 
strain 1 and 2 (Table 2). Similarly, the Col-R strains 1 and 3 with point 
mutations in PmrB (V21 → F, S28 → R, I149 → F) and LpxA/C (N136 → 
K/ P293 → Q) displayed high MIC level (32 μg/mL) against colistin. The 
phylogenetic tree analysis of the PmrB with those closely related se-
quences reported in the GenBank database including A. baumannii 
AEK67613.1 and WP_104915345.1 showed 86% identity. While, 
phylogenetic evaluation of PmrA revealed 99.6% sequence identity with 
PmrA of A. baumannii WP_005130952.1 and WP_147264849.1, respec-
tively (Fig. 3A and B). The results suggested no evolutionary relationship 
base on PmrB sequences in this study with those reported in the Gen-
Bank database. Consequently, we carried out multiple amino acid 
alignments of PmrA/B with closely related sequences of A. baumannii. 
We found two substitutions (V21 → F and S28 → R) in the trans-
membrane domain of PmrB (Fig. 4). However, histidine kinase and 
HATPase_ c domains remained intact. 
4. Discussion 
Carbapenemase producing A. baumannii create overwhelming 
problem in the treatment of patients suffering from immunodeficiency, 
cancer, cystic fibrosis, and diabetes type II. Molecular studies not only 
expose serious strategies for controlling the outbreak of these isolates 
but also to identify potential new targets for antimicrobial drug devel-
opment (Leite et al., 2019). Colistin, or its prodrug CMS, is a key ther-
apeutic option for treatment of carbapenem-resistant A. baumannii alone 
or in combination with other agents such as tigecycline, ampicillin- 
sulbactam, rifampin, and carbapenems (Pogue et al., 2013). The US 
CAPITAL 2010 surveillance data showed colistin was the most effective 
agent tested, with 95% susceptibility (Queenan et al., 2012). In Europe, 
the evolving colistin resistance is more pronounced in southern coun-
tries (notably Greece, Romania, and Italy) for example, data from nine 
hospitals involved in Greece indicates, 32.8% of the carbapenemase- 
producing A. baumannii isolates were also resistant to colistin (Pourna-
ras et al., 2017). However, there is no report on the frequency and 
mechanism of colistin resistance in southeast Iran. 
Here, we investigated the prevalence and molecular mechanism of 
the colistin-resistance in A. baumannii clinical isolates. We found that 
overall, the prevalence of Col-R A. baumannii is low in Kerman prove-
nience as compared to other part of Iran. However, these isolates 
exhibited XDR phenotype and have also been resistant to carbapenems, 
aminoglycosides, quinolones, and third generations of cephalosporins 
but were sensitive to tigecycline and ampicillin-sulbactam. Therefore, 
these two antibiotics especially ampicillin-sulbactam can be used for 
treatment of these isolates. Nevertheless, none of the Col-R strains were 
exposed to colistin previously. Molecular typing by MLST revealed that, 
the isolates belonged to a novel domestic MLST allele, ST-1752 reported 
by us for the first time and clonal complex 2. The MLST results were 
highly correlated with RAPD-PCR typing. Therefore, we proposed that 
they are indeed emerged from single clonal ancestor. To further confirm 
this hypothesis, the phylogenetic tree construction of A. baumannii 
PmrA/B with similar sequences in the GenBank database was carried 
out. The results showed low similarity with reported sequences. Since 
Col-R isolates originated from same ICU, it is possible that, the ST-1752 
Col-R strains were emerged by endogenous mutations rather than 
acquisition of preexisting clones over a period of time. In this context, 
the assessment of our data highlighted that response to colistin is highly 
variable among the Col-R A. baumannii strains depend upon types and 
positions of mutations occur in the pmrB and lpx genes (MICs varied 
from 4, 8, and 32 μg/mL). Further, the transcriptional analysis of 
A. baumannii isolates revealed 8-fold increases in the mRNA level of 
pmrB in presence of sub-MIC of colistin. This was associated with a 7-fold 
increase in pmrC activity. The expressional evaluation showed, increase 
in transcription of pmrB was strain dependent process and probably up 
regulate of pmrC expression in A. baumannii strain 1. Moreover, full- 
length DNA sequencing of lpxACD genes revealed, a point mutation in 
LpxA (N136 → K), and LpxC (P293 → Q) along with two amino acids 
substitutions in PmrB of the strains 1 and 3 that exhibiting high MIC (32 
μg/mL) against colistin. Furthermore, multiple amino acid alignments of 
PmrA/B with closely related sequences of A. baumannii detected two 
substitutions (V21 → F and S28 → R) in the transmembrane domain of 
PmrB. In contrast, histidine kinase and HATPase_ c domains remained 
intact. 
A previous report by Moffatt et al. (2010) revealed that, the strains 
develop colistin resistance due to lpx mutations need to modulate the 
composition and structure of the bacterial surface in response to the lack 
of LPS. Recently screening of a transposon TnSeq mutant library iden-
tified over 30 genes involved in inducible colistin-resistance in 
A. baumannii. One of the genes identified was lpsB, which encodes a 
glycosyltransferase involved in LPS synthesis (Zhang et al., 2017). 
Whole-genome sequencing analysis of the Col-R A. baumannii strains 
revealed that, the main causes of the resistance to colistin were muta-
tions in the pmrA-pmrB genes, including pmrAP102 → R, pmrBP233 → S, 
pmrBT235 → N, and the novel alleles pmrAI13 → M and pmrBQ270 → P 
(Sun et al., 2020). Similar to our work, Saleh et al. (2020) reported that 
two amino acid substitutions (A95 → T and P157 → R) in the trans-
membrane domains of PmrB cause low-level resistance to colistin. 
Another mechanism of Col-R in A. baumannii has been attributed to 
mutations in EmrAB family efflux pumps (Lin et al., 2017). Using 
phenotypic microarray analysis, the A. baumannii ΔemrB mutants was 
more susceptible to colistin, nafcillin, paromomycin, spiramycin, and D, 
L-serine hydroxamate than the wild type. The spot assay, time-kill assay, 
and MIC test indicated that, the wild type A. baumannii could tolerate 
colistin better than the ΔemrB mutant strains. The increased expression 
levels of all emrB like genes, including A1S_0775, A1S_0909, A1S_1772, 
and A1S_1799, in Col-R A. baumannii further supported the possible 
involvement of the emrB efflux pump genes in A. baumannii colistin- 
resistance (Lin et al., 2017). 
5. Conclusion 
In conclusion, overall rate of colistin resistance A. baumannii in our 
Table 2 
Mutational analyses of lpxACD and two-component regulatory system pmrA/B 
genes in colistin- resistant isolates of A. baumannii obtained from hospital 
specimens.  
Isolate 
no. 
CLS 
MICs 
(μg/ 
mL) 
Amino acid substitutions 
PmrA PmrB LpxA LpxC LpxD 
1  32 Q218K L5F, S12R, 
V16D, L18I, 
V21F, S28R, 
L25S, R35E, 
36P, H39P, 
T53S, F60L, 
I61S, D62E, 
I63Y, Y66N, 
F88I 
N136K Wild 
type 
Wild 
type 
2  8 Q218K L5F, C7W, 
C8Y, V112F, 
D355E, 
S356W, 
P362L, E363G, 
Y373 → F 
Wild 
type 
Wild 
type 
K318T, 
I320E, 
322V 
3  32 Q218K L5F, I149F, 
T331P 
Wild 
type 
P293Q K318M 
4  4 Wild 
type 
L5F, T172P, 
P362L 
Wild 
type 
G277R K318M 
Note: The point mutations were either transition or transversion. In pmrA 
identical base substitution occurred at position 218 in three strains of Col-R 
A. baumannii. The PmrB in strains 1 and 2 exhibited high number and di-
versity in the amino acids substitutions many of which were unique and reported 
by us for the first time. 
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hospitals was low as compared to other regions of Iran. The majority of 
the isolates showed MDR phenotypes. However, four XDR isolates 
showed resistant to colistin with different MIC levels. These strains were 
also displayed high MIC to imipenem. The Col-R isolates were belonged 
to a novel, St Type. Interestingly, the phylogenetic tree analysis revealed 
no evolutionary relationship among A. baumannii PmrB in this study 
with other similar proteins sequences reported in the GenBank database 
indicates that these strains emerged spontaneously. Consequently, all 
mutations found in this study were unique and differed in type and 
position to the other reports in A. baumannii. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.genrep.2020.100952. 
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